Thailand

Key Insights

1
No psychedelic therapy is approved for routine patient use in Thailand; psilocybin remains illegal, while ketamine is medically available under controlled narcotics rules.
2
Thailand’s database shows 1 trial, 0 active, 1 organisation, with ketamine and placebo as the only studied compounds.
3
Thailand’s first randomised controlled ketamine depression trial, published in 2024, was described by authors as the country’s first ketamine RCT.
4
Momentum sits with Mahidol University: the lone registered study and publication anchor Thailand’s clinical ketamine work, but no active psychedelic trials are now listed.

Medical Only (Private)

Reimbursed Care Access

Thailand maintains a tightly regulated approach to classical psychedelics: some compounds (notably ketamine) are established in medical practice while others remain scheduled with access limited to research or prohibited outside of strict controls. A 2024 ministerial notification explicitly opened a regulatory pathway for psilocybin research/medical use, but most serotonergic psychedelics (MDMA, DMT, mescaline, 2C-X, etc.) remain controlled with no routine clinical/reimbursed access.

Full guide →